Trial intelligence / Profile preview

Cervarix in HIV-infected women

NCT00586339Phase 2Completed

Sponsor
GSK
Start
Jan 2008
Primary completion
Jul 2011
Modality
Vaccines & Immunotherapeutics
Countries
1
01

Overview

A Phase 2 trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection, sponsored by GSK. Started Jan 2008; status: completed.

02

Drugs

Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03

Conditions

human papillomavirus infection

Beyond the preview

Go deeper on NCT00586339.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00586339.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call